Cypherpunk Technologies (CYPH) – Research Analysts’ Recent Ratings Changes

Cypherpunk Technologies (NASDAQ: CYPH) recently received a number of ratings updates from brokerages and research firms:

• 7/4/2026 – Cypherpunk Technologies was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/3/2026 – Cypherpunk Technologies was upgraded by Cantor Fitzgerald to “strong-buy”.
• 7/1/2026 – Cypherpunk Technologies is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $0.90 price target on the stock.
• 7/1/2026 – Cypherpunk Technologies is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $0.90 price target on the stock.
• 6/25/2026 – Cypherpunk Technologies was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/21/2026 – Cypherpunk Technologies was downgraded by Weiss Ratings from “sell (d+)” to “sell (d-)”.
• 5/16/2026 – Cypherpunk Technologies was downgraded by Wall Street Zen from “hold” to “sell”.

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.